Table 2 Antibodies with a potent neutralizing effect against pseudovirus or authentic virus SARS-CoV-2 infection
Name/class | Source | KD (nM) | IC50 μg/mL | Target | Observations | References |
|---|---|---|---|---|---|---|
CV07-250/C1 | B cells from C-CoV-2 | 0.056 | 0.0035 (AV-CoV-2) | RBD | Reduced hACE2 binding and showed no binding to murine tissue | [17] |
BD-604/C1 | B cells from C-CoV-2 | 0.15 | 0.005 (PSV-CoV-2) | RBD up | BD-604 binds to RBD ~ 19-fold higher than BD-236 and is more potent against the SARS-CoV-2 pseudovirus, compared to BD-236 | [140] |
BD-629/C1 | B cells from C-CoV-2 | 0.006 | 0.004 (PSV-CoV-2) | RBD up | Genes coding for BD-629 are different compared to BD-604. However, its affinity and neutralization against the SARS-CoV-2 pseudovirus are similar | [140] |
CV07-209/C1 | B cells from C-CoV-2 | 0.056 | 0.003 (AV-CoV-2) | RBD | Prophylactic and therapeutic efficacy in golden Syrian hamsters. Therapeutic mAb reduced signs of COVID-19, although 1/3 animals presented mild bronchopulmonary, pneumonia and endothelialitis | [17] |
COVA1-18/C1 | B cells from C-CoV-2 | 0.03 (S) 0.9 (RBD) | 0.008 (PSV-CoV-2) 0.007 (AV-CoV-2) | RBD | A strong competition with hACE2 was observed, suggesting blocking hACE2 is it mechanism of neutralization | [136] |
CC6.29/C1 | B cells from C-CoV-2 | 1.2 | 0.002 (PSV-CoV-2) 0.0071 (AV-CoV-2) | RBD-A | mAb exhibited a potent neutralization | [16] |
COV2-2196/C1 | B cells from C-CoV-2 | – | 0.0007 (PSV-CoV-2) 0.015 (AV-CoV-2) | S2Pecto open | A strong competition with hACE2. Prophylactic efficacy in rhesus macaques (50 mg/Kg) and mice (200 µg per mouse) reducing lung disease. Therapeutic efficacy in mice (20 mg kg−1) | [208] |
BD-368–2/C2 | B cells from C-CoV-2 | 0.82 | 0.0012 (PSV-CoV-2) 0.015 (AV-CoV-2) | RBD “up/down” | Changes the S trimer conformation contributing to its neutralizing activity. Prophylactic efficacy: IP 20 mg/kg mAb 24 h before infection. Therapeutic efficacy: IP 20 mg/kg of mAb 2 h after infection into hACE2 transgenic mice | [32] |
COV2-2130/C2 | B cells from C-CoV-2 | – | 0.0016 (PSV-CoV-2) 0.107 (AV-CoV-2) | S2Pecto closed | Blocked the binding of SARS-CoV-2 to hACE2. Prophylactic efficacy in rhesus macaques (50 mg/Kg) and mice (200 µg per mouse) developing less lung disease. Therapeutic (20 mg kg−1) efficacy in mice | [208] |
C12-04/C2 | B cells from C-CoV-2 | 2.3 (S) 11.2 (RBD) | 0.220 (PSV-CoV-2) 0.002 (AV-CoV-2) | RBD “up”/“down” | Potent neutralizing mAB, suggest the blocks the engagement of hACE2 as a main mechanism of neutralization | [136] |
C119/C2 | PMBC´s from C-CoV-2 | 10.0 (RBD) | 0.009 (PSV-CoV-2) | RBD “up”/“down” | It was proposed a quaternary interaction with RBD in down conformation adjacent to an “up” RBD, as well could interacts between two adjacent down RBD domains. Showed a binding pose similar to REGN10987′s | |
C121/C2 | PMBC´s from C-CoV-2 | 0.5 (RBD) | 0.0067 (PSV-CoV-2) 0.00164 (AV-CoV-2) | RBD “up”/“down” | Quaternary binding with RBD in down adjacent to an “up” RBD was proposed, and could interacts between two adjacent down RBD, with a binding pose similar to REGN10987′s | |
C144/C2 | PMBC´s from C-CoV-2 | 18.0 (RBD) | 0.0069 (PSV-CoV-2) 0.0025 (AV-CoV-2) | RBD “up”/“down” | Quaternary binding, in the “down” RBD conformation. different from C002, C121, C119, C104 | |
COVA2-15/C2 | B cells from C-CoV-2 | 0.6 (S) 3.1 (RBD) | 0.008 (PSV-CoV-2) 0.009 (AV-CoV-2) | RBD “up”/“down” | A strong competition with hACE2 binding, binding RBD in "up" and "down" conformations, while its epitope is partially overlapped with the hACE2-binding site | [136] |
2–15/C2 | B cells from C-CoV-2 | 0.056 | 0.005 (PSV-CoV-2) 0.0007 (AV-Cov-2) | RBD “up”/“down” | Exhibited high potency in neutralizing in vitro, in a protection experiments using golden Syrian hamster reduced the infectious virus titres by 4 logs (1.5 mg/kg) | |
C002/C2 | PBMC from C-CoV-2 | 11 (RBD) | 0.009 (PSV-CoV-2) | RBD “up”/“down” | Quaternary binding to “up/down” RBDs like C121, but different to C144. Interaction with RBD in down conformation adjacent to an “up” RBD, probably interacts between two adjacent "down" RBD domains | |
C135/C3 | PMBC´s from C-CoV-2 | 6.0 (RBD) | 0.016 (PSV-CoV-2) 0.0029 (AV-CoV-2) | RBD “up”/“down” | Three C135 Fabs bound with 2 “down” and 1 “up” RBDs (interaction weakly resolved), recognizing the glycosylated epitope N343RBD, interacting with R346 and N440, without steric hindrance between hACE2 / RBD | |
2–51/C3 | B cells from C-CoV-2 | 3.6 | 0.005 (PSV-CoV-2) 0.0007 (AV-Cov-2) | NTD | Potent neutralizing antibody against PSV-CoV-2 and AV-Cov-2 in vitro | [207] |
H014/C4 | phage display antibody library | 0.09 | 3 nM (PSV-CoV-2) 38 nM (AV-CoV-2) | RBD up class 4 | hACE2-humanized mice injected IP 50 mg per kilogram either 4 h after (one dose, therapeutic) or 12 h before and 4 h after (two doses, prophylactic plus therapeutic) with SARS-CoV-2 infection. No lesions of alveolar epithelial cells | [4] |
5–24/WO | B cells from C-CoV-2 | 0.013 (PSV-CoV-2) 0.008 (AV-CoV-2) | NTD | nAb with high potency against AV-Cov-2 in vitro | [205] | |
1–57/WO | B cells from C-CoV-2 | 0.056 | 0.009 (PSV-CoV-2) 0.008 (AV-CoV-2) | RBD | mAb exhibited high potency in neutralizing AV-Cov-2 in vitro | [205] |
2–7/WO | B cells from C-CoV-2 | 0.056 | 0.010 (PSV-CoV-2) 0.003 (AV-CoV-2) | RBD | mAb exhibited high potency in neutralizing AV-Cov-2 in vitro | [205] |